S D Patterson

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi request reprint Application of combined mass spectrometry and partial amino acid sequence to the identification of gel-separated proteins
    S D Patterson
    Amgen Inc, Thousand Oaks, CA, USA
    Electrophoresis 17:877-91. 1996
  2. doi request reprint The role of biomarkers in the future of drug development
    Scott D Patterson
    Department of Molecular Sciences, Amgen, Inc, 1 Amgen Center Drive, MS 38 3 A Thousand Oaks, CA 91320, USA
    Expert Opin Drug Discov 1:199-204. 2006
  3. pmc A comparability study of 5 commercial KRAS tests
    Kelly Oliner
    Department of Molecular Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Diagn Pathol 5:23. 2010
  4. ncbi request reprint Proteomics: the industrialization of protein chemistry
    S D Patterson
    Amgen Inc, Biochemistry, Thousand Oaks, California 91320 1789, USA
    Curr Opin Biotechnol 11:413-8. 2000
  5. ncbi request reprint Report from the Wellcome Trust/EBA “Perspectives in Clinical Proteomics” retreat--a strategy to implement next-generation proteomic analyses to the clinic for patient benefit: pathway to translation
    Scott D Patterson
    Medical Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Proteomics Clin Appl 4:883-7. 2010
  6. doi request reprint Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group
    Scott D Patterson
    Medical Sciences, Amgen Inc, 1 Amgen Center Drive MS 38 3 A, Thousand Oaks, CA 91320, USA
    Pharmacogenomics 12:939-51. 2011
  7. ncbi request reprint Mutation of Cys672 allows recombinant expression of activatible macrophage-stimulating protein
    R C Wahl
    Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    J Biol Chem 272:15053-6. 1997
  8. ncbi request reprint Automated LC-LC-MS-MS platform using binary ion-exchange and gradient reversed-phase chromatography for improved proteomic analyses
    M T Davis
    Department of Biochemistry, Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Chromatogr B Biomed Sci Appl 752:281-91. 2001
  9. ncbi request reprint Protein identification and characterization by mass spectrometry
    S D Patterson
    Amgen, Inc, Thousand Oaks, California, USA
    Curr Protoc Mol Biol . 2001
  10. doi request reprint The value of banked samples for oncology drug discovery and development
    Peter M Shaw
    Department of Genetics, Early Translational Sciences, Merck Research Laboratories, West Point, PA, USA
    J Natl Cancer Inst Monogr 2011:46-9. 2011

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Application of combined mass spectrometry and partial amino acid sequence to the identification of gel-separated proteins
    S D Patterson
    Amgen Inc, Thousand Oaks, CA, USA
    Electrophoresis 17:877-91. 1996
    ..In one case the identified protein clearly did not correspond to the radiolabeled band, but to a protein contaminant from the column. The advantages and pitfalls of the approach are discussed...
  2. doi request reprint The role of biomarkers in the future of drug development
    Scott D Patterson
    Department of Molecular Sciences, Amgen, Inc, 1 Amgen Center Drive, MS 38 3 A Thousand Oaks, CA 91320, USA
    Expert Opin Drug Discov 1:199-204. 2006
    ..The strategy to achieve these aims and how this can lead to information that can be fed back into drug discovery is described in this perspective...
  3. pmc A comparability study of 5 commercial KRAS tests
    Kelly Oliner
    Department of Molecular Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Diagn Pathol 5:23. 2010
    ..Therefore, an accurate and readily available analysis of KRAS mutational status is needed. The aim of this study was to evaluate concordance between KRAS assays performed by 6 different laboratories...
  4. ncbi request reprint Proteomics: the industrialization of protein chemistry
    S D Patterson
    Amgen Inc, Biochemistry, Thousand Oaks, California 91320 1789, USA
    Curr Opin Biotechnol 11:413-8. 2000
    ....
  5. ncbi request reprint Report from the Wellcome Trust/EBA “Perspectives in Clinical Proteomics” retreat--a strategy to implement next-generation proteomic analyses to the clinic for patient benefit: pathway to translation
    Scott D Patterson
    Medical Sciences, Amgen Inc, Thousand Oaks, CA, USA
    Proteomics Clin Appl 4:883-7. 2010
    ..Although not meant to be all encompassing, important elements for proteomics researchers to consider are presented...
  6. doi request reprint Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group
    Scott D Patterson
    Medical Sciences, Amgen Inc, 1 Amgen Center Drive MS 38 3 A, Thousand Oaks, CA 91320, USA
    Pharmacogenomics 12:939-51. 2011
    ..The primary utility of the PRA is to define a process that provides robust scientific evidence for decision-making in situations where it is not necessary, nor practical or ethical to conduct a new prospective clinical study...
  7. ncbi request reprint Mutation of Cys672 allows recombinant expression of activatible macrophage-stimulating protein
    R C Wahl
    Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    J Biol Chem 272:15053-6. 1997
    ....
  8. ncbi request reprint Automated LC-LC-MS-MS platform using binary ion-exchange and gradient reversed-phase chromatography for improved proteomic analyses
    M T Davis
    Department of Biochemistry, Amgen, Inc, Thousand Oaks, CA 91320, USA
    J Chromatogr B Biomed Sci Appl 752:281-91. 2001
    ..In comparative analyses of a highly complex peptide digest mixture a >40% increase in the number of peptide and protein identifications was achieved using this multidimensional platform compared to an unfractionated control...
  9. ncbi request reprint Protein identification and characterization by mass spectrometry
    S D Patterson
    Amgen, Inc, Thousand Oaks, California, USA
    Curr Protoc Mol Biol . 2001
    ..The mass spectrometric methods referred to in this overview include matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and electrospray ionization mass spectrometry (ESI-MS)...
  10. doi request reprint The value of banked samples for oncology drug discovery and development
    Peter M Shaw
    Department of Genetics, Early Translational Sciences, Merck Research Laboratories, West Point, PA, USA
    J Natl Cancer Inst Monogr 2011:46-9. 2011
    ....